64. 血栓性血小板減少性紫斑病 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 109 / 薬物数 : 67 - (DrugBank : 17) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 75

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ALX-0081
   ABLYNX N.V.
      2010   -   EUCTR2010-019375-30-IT   Austria;Belgium;Germany;Italy;Spain;United Kingdom
   ABLYNX NV
      -   Phase 3   EUCTR2016-001503-23-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2015-001098-42-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Ablynx
      2011   -   EUCTR2010-019375-30-ES   Austria;Belgium;Germany;Italy;Spain;United Kingdom
      2010   Phase 2   EUCTR2010-019375-30-GB   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2010-019375-30-DE   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2010   Phase 2   EUCTR2010-019375-30-BE   Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2010-019375-30-AT   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Ablynx NV
      2017   Phase 3   EUCTR2016-001503-23-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-GB   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-CZ   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-BE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-AT   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001098-42-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2015-001098-42-Outside-EU/EEA   Australia;Canada;Israel;Switzerland;Turkey;United States
   Sanofi
      2019   Phase 2/Phase 3   NCT04074187   Japan
ALX0081
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2022   Phase 3   EUCTR2022-001177-31-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2023   Phase 3   EUCTR2022-001177-31-GR   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001177-31-AT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-NL   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-DE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-CZ   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche et Développement
      2022   Phase 3   EUCTR2022-001177-31-BE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
Anfibatide
   Lee's Pharmaceutical Limited
      2019   Phase 2   NCT04021173   China
ANTI-CD20 antibody
   Sanofi
      2022   Phase 3   NCT05468320   Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   Tanaka Tomoyuki
      2023   Phase 3   JPRN-jRCT2031230030   Austria;Belgium;Czechia;France;Germany;Japan;Netherlands;Spain;United Kingdom;United States
ANTI-VON willebrand factor nanobody
   ABLYNX N.V.
      2010   -   EUCTR2010-019375-30-IT   Austria;Belgium;Germany;Italy;Spain;United Kingdom
   ABLYNX NV
      -   Phase 3   EUCTR2016-001503-23-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2015-001098-42-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Ablynx
      2011   -   EUCTR2010-019375-30-ES   Austria;Belgium;Germany;Italy;Spain;United Kingdom
   Ablynx NV
      2017   Phase 3   EUCTR2016-001503-23-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-GB   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-CZ   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-BE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-AT   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
ANTI-VON willebrand factor nanobody, caplacizumab
   Ablynx
      2010   -   EUCTR2010-019375-30-DE   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2010   -   EUCTR2010-019375-30-AT   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
ANTI-VON willebrand factor nanobody, INN = caplacizumab
   Ablynx
      2010   Phase 2   EUCTR2010-019375-30-GB   Austria;Belgium;Canada;Germany;Israel;Italy;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2010   Phase 2   EUCTR2010-019375-30-BE   Australia;Austria;Belgium;Germany;Israel;Italy;Spain;Switzerland;United Kingdom;United States
Apadamtase alfa
   BAXALTA INNOVATIONS GMBH
      2022   Phase 3   EUCTR2020-003348-10-IT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 2   EUCTR2018-003775-35-IT   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-IT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovation GmbH
      2019   Phase 2   EUCTR2018-003775-35-DE   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2022   Phase 3   EUCTR2020-003348-10-DE   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-FR   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-ES   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-AT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003348-10-GB   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-GB   Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-ES   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-FR   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-DE   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-GB   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-ES   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003348-10-PL   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-000858-18-PL   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-GR   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-ES   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
Apademtase alfa
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
ARC 1779
   Archemix Corp.
      2008   Phase 2   NCT00726544   Austria;Canada;Italy;United Kingdom;United States
      2007   -   EUCTR2007-004371-19-AT   Austria
ARC1779 injection
   Archemix Corp.
      2008   Phase 2   NCT00726544   Austria;Canada;Italy;United Kingdom;United States
      2007   -   EUCTR2007-004371-19-AT   Austria
Aspirin tablet
   The First Affiliated Hospital of Soochow University
      2022   Phase 2/Phase 3   NCT05568147   -
BAX930
   Baxalta Innovations GmbH
      2015   -   EUCTR2012-003221-19-PL   Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States
      2015   Phase 1   EUCTR2012-003221-19-DE   Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003221-19-GB   Austria;Germany;Japan;Poland;United Kingdom;United States
      2012   -   EUCTR2012-003221-19-AT   Austria;Germany;Japan;Poland;United Kingdom;United States
   Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
      2019   Phase 3   JPRN-jRCT2080224906   Europe;Japan;North America
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-AT   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
BAX930 - recombinant human adamts13
   BAXALTA INNOVATIONS GMBH
      2020   Phase 2   EUCTR2018-003775-35-IT   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovation GmbH
      2019   Phase 2   EUCTR2018-003775-35-DE   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2019   Phase 2   EUCTR2018-003775-35-GB   Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-ES   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-GR   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-ES   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
BAX930 or SHP655
   BAXALTA INNOVATIONS GMBH
      2022   Phase 3   EUCTR2020-003348-10-IT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-IT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2022   Phase 3   EUCTR2020-003348-10-DE   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-ES   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-AT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003348-10-GB   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-FR   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-GB   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-ES   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003348-10-PL   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2017-000858-18-PL   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
BAX930 or SHP655 or TAK755
   Baxalta Innovations GmbH
      2019   Phase 3   EUCTR2017-000858-18-DE   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
BMS-986413
   Imperial College Healthcare NHS Trust
      2021   Phase 2   NCT05393999   United Kingdom
BMS-986414
   Imperial College Healthcare NHS Trust
      2021   Phase 2   NCT05393999   United Kingdom
Bortezomib injection
   Peking Union Medical College Hospital
      2021   Phase 4   NCT05135442   China
Cablivi
   CHU de Rouen
      2020   Phase 2   EUCTR2020-005288-30-FR   France
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2022   Phase 3   EUCTR2022-001177-31-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2023   Phase 3   EUCTR2022-001177-31-GR   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001177-31-AT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-NL   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-DE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-CZ   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche et Développement
      2022   Phase 3   EUCTR2022-001177-31-BE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   University of Cologne
      2023   -   NCT05876221   Germany
      2021   -   NCT04985318   Germany
Cablivi®
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2022-001177-31-FR   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
Caplacizumab
   ABLYNX NV
      -   Phase 3   EUCTR2016-001503-23-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2015-001098-42-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
   Ablynx NV
      2017   Phase 3   EUCTR2016-001503-23-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001503-23-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-GB   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-CZ   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-BE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2016-001503-23-AT   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-001098-42-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-HU   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-ES   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001098-42-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2015-001098-42-Outside-EU/EEA   Australia;Canada;Israel;Switzerland;Turkey;United States
   Ablynx, a Sanofi company
      2015   Phase 3   NCT02553317   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   NCT01151423   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Romania;Spain;Switzerland;United Kingdom;United States
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2022   Phase 3   EUCTR2022-001177-31-IT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi
      2022   Phase 3   NCT05468320   Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2022   -   NCT05263193   France
      2019   Phase 2/Phase 3   NCT04074187   Japan
      2016   Phase 3   NCT02878603   Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2023   Phase 3   EUCTR2022-001177-31-GR   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001177-31-AT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-NL   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-DE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-CZ   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche et Développement
      2022   Phase 3   EUCTR2022-001177-31-BE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Tanaka Tomoyuki
      2023   Phase 3   JPRN-jRCT2031230030   Austria;Belgium;Czechia;France;Germany;Japan;Netherlands;Spain;United Kingdom;United States
   University Hospital, Rouen
      2021   Phase 2   NCT04720261   -
Corticosteroids
   New England Research Institutes
      2009   Phase 3   NCT00799773   United States
   Sanofi
      2022   Phase 3   NCT05468320   Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   Tanaka Tomoyuki
      2023   Phase 3   JPRN-jRCT2031230030   Austria;Belgium;Czechia;France;Germany;Japan;Netherlands;Spain;United Kingdom;United States
Cryosupernatant plasma
   Octapharma
      2007   Phase 3   NCT00411801   United States
Cyclosporine
   Ohio State University
      2007   Phase 3   NCT00713193   United States
Danazol
   Icahn School of Medicine at Mount Sinai
      2008   Phase 2   NCT00953771   United States
Desmopressin acetate
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
Dexamethasone
   David Gomez Almaguer
      2020   Phase 2   NCT04588194   Mexico
Efgartigimod
   University of Minnesota
      2025   Phase 2   NCT06831058   -
HMED-ides
   Hansa Medical AB
      2016   Phase 2   EUCTR2016-000249-30-GB   United Kingdom
IDEC-C2b8, RO 45-2294
   University College London
      2005   Phase 2   EUCTR2005-002274-30-GB   United Kingdom
Ides
   Hansa Biopharma AB
      2016   Phase 2   NCT02854059   United Kingdom
Mabthera
   FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2010   -   EUCTR2010-018794-38-IT   Italy
   University College London
      2017   Phase 4   EUCTR2017-001117-86-GB   United Kingdom
      2005   Phase 2   EUCTR2005-002274-30-GB   United Kingdom
Methylprednisolone
   Sanofi
      2019   Phase 2/Phase 3   NCT04074187   Japan
Minirin
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
Nanobody directed towards THE human A1 domain OF VON willebrand factor
   Sanofi-Aventis Recherche & Développement
      2023   Phase 3   EUCTR2022-001177-31-GR   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001177-31-AT   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-NL   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-DE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001177-31-CZ   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
   Sanofi-Aventis Recherche et Développement
      2022   Phase 3   EUCTR2022-001177-31-BE   Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Japan;Netherlands;Spain;Switzerland;United Kingdom;United States
Octaplas
   Octapharma
      2017   -   NCT01938404   United States
Octaplas infusion
   St. Olavs Hospital
      2012   Phase 4   NCT01754545   Norway
Octaplas SD
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
Octaplas®LG
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
Octostim
   Archemix Corp.
      2007   -   EUCTR2007-004371-19-AT   Austria
OMS721 100 MG/ML injection solution, OMS00620646, OMS620646, MASP-2 antibody
   OMEROS CORPORATION
      -   Phase 2   EUCTR2014-001032-11-IT   Belarus;Belgium;Bulgaria;Czechia;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Omeros Corporation
      2014   Phase 2   EUCTR2014-001032-11-PL   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-LT   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-BE   Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
OMS721 185 MG/ML injection solution, OMS00620646, OMS620646, MASP-2 antibody
   Omeros Corporation
      2014   Phase 2   EUCTR2014-001032-11-PL   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-LT   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
Plasma exchange
   New England Research Institutes
      2009   Phase 3   NCT00799773   United States
   Sanofi
      2019   Phase 2/Phase 3   NCT04074187   Japan
Pooled plasma (human), solvent/detergent treated
   Baxalta Innovations GmbH
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
Prednisolone
   Sanofi
      2019   Phase 2/Phase 3   NCT04074187   Japan
Prednisone
   Ohio State University
      2007   Phase 3   NCT00713193   United States
Radamts-13
   Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
      2019   Phase 3   JPRN-jRCT2080224906   Europe;Japan;North America
Radamts13
   BAXALTA INNOVATIONS GMBH
      2020   Phase 2   EUCTR2018-003775-35-IT   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovation GmbH
      2019   Phase 2   EUCTR2018-003775-35-DE   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2019   Phase 2   EUCTR2018-003775-35-GB   Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-ES   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-GR   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-ES   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-AT   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
Recombinant A disintegrin and metalloproteinase thrombospondin TYPE-1 motifs 13
   BAXALTA INNOVATIONS GMBH
      2022   Phase 3   EUCTR2020-003348-10-IT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2022   Phase 3   EUCTR2020-003348-10-DE   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-FR   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-ES   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-AT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003348-10-GB   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2020-003348-10-PL   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Recombinant A disintegrin and metalloproteinase with thrombospondin TYPE-1 motifs
   Baxalta Innovations GmbH
      2022   Phase 3   EUCTR2020-003348-10-DE   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-FR   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-ES   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-AT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003348-10-GB   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2020-003348-10-PL   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Recombinant A disintegrin and metalloproteinase with thrombospondin TYPE-1 motifs 13
   BAXALTA INNOVATIONS GMBH
      2020   Phase 2   EUCTR2018-003775-35-IT   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-IT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovation GmbH
      2019   Phase 2   EUCTR2018-003775-35-DE   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2019   Phase 2   EUCTR2018-003775-35-GB   Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-ES   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-FR   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2017-000858-18-DE   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000858-18-AT   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-GB   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000858-18-ES   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
      2015   -   EUCTR2012-003221-19-PL   Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States
      2015   Phase 1   EUCTR2012-003221-19-DE   Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States
      2013   Phase 1   EUCTR2012-003221-19-GB   Austria;Germany;Japan;Poland;United Kingdom;United States
      2012   -   EUCTR2012-003221-19-AT   Austria;Germany;Japan;Poland;United Kingdom;United States
      -   Phase 3   EUCTR2017-000858-18-PL   Austria;Canada;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-GR   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-ES   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-AT   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
Recombinant adamts13
   Baxalta now part of Shire
      2014   Phase 1   NCT02216084   Austria;Germany;Japan;Poland;Switzerland;United Kingdom;United States
   Takeda
      2024   -   NCT06441578   Japan
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT00907751   France
   David Gomez Almaguer
      2020   Phase 2   NCT04588194   Mexico
   FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2010   -   EUCTR2010-018794-38-IT   Italy
   Hamilton Health Sciences Corporation
      2007   Phase 2   NCT00531089   Canada
   New England Research Institutes
      2009   Phase 3   NCT00799773   United States
   Saitama Medical University , Department of General Internal Medicine, Yoshitaka Miyakawa
      2014   Phase 2   JPRN-jRCT2091220160   Japan
   Sanofi
      2019   Phase 2/Phase 3   NCT04074187   Japan
   Tanaka Tomoyuki
      2023   Phase 3   JPRN-jRCT2031230030   Austria;Belgium;Czechia;France;Germany;Japan;Netherlands;Spain;United Kingdom;United States
   The First Affiliated Hospital Of Soochow University
      2013   Phase 1 study   ChiCTR-ONRC-13003194   China
   University College, London
      2006   Phase 2   NCT00937131   United Kingdom
   Washington University School of Medicine
      2012   Phase 2   NCT01554514   United States
   Weill Medical College of Cornell University
      2005   Phase 1/Phase 2   NCT00251277   United States
Romiplostim
   David Gomez Almaguer
      2020   Phase 2   NCT04588194   Mexico
SHP655
   BAXALTA INNOVATIONS GMBH
      2020   Phase 2   EUCTR2018-003775-35-IT   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovation GmbH
      2019   Phase 2   EUCTR2018-003775-35-DE   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Baxalta Innovations GmbH
      2019   Phase 2   EUCTR2018-003775-35-GB   Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003775-35-ES   Canada;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Shire
      2019   Phase 2   NCT03922308   Canada;France;Germany;Italy;Spain;United Kingdom;United States
Standard plasma
   Octapharma
      2017   -   NCT01938404   United States
Sulfate, magnesium
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03237819   France
TAK-755
   Baxalta now part of Shire
      2017   Phase 3   NCT03393975   Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Takeda
      2023   -   NCT05770219   -
      2023   Phase 2   NCT05714969   Argentina;Austria;Canada;Germany;Greece;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 3   NCT04683003   Austria;China;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom;United States
   Takeda Development Center Americas, Inc.
      2023   Phase 2   EUCTR2022-001940-36-GR   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001940-36-ES   Argentina;Austria;Canada;France;Germany;Greece;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
TAK-755 or BAX930 or SHP655
   Baxalta Innovations GmbH
      2021   Phase 3   EUCTR2020-003348-10-FR   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
TAK-755 orbax930 or SHP655
   BAXALTA INNOVATIONS GMBH
      2022   Phase 3   EUCTR2020-003348-10-IT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
   Baxalta Innovations GmbH
      2022   Phase 3   EUCTR2020-003348-10-DE   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-ES   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003348-10-AT   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003348-10-GB   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2020-003348-10-PL   Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Russian Federation;Serbia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Uniplas
   Octapharma
      2007   Phase 3   NCT00411801   United States
Water
   Baxalta now part of Shire(ICCC: IQVIA Services Japan K.K.)
      2019   Phase 3   JPRN-jRCT2080224906   Europe;Japan;North America